Last updated: April 25, 2026
What does Colombia patent CO6700856 cover, and how broad are its claims?
CO6700856 is a Colombian national phase within the WO/EP family for the small-molecule GLP-1 receptor agonist “semaglutide”. The patent’s scope is directed to pharmaceutical compositions and dosing regimens of semaglutide (and related salts/forms as claimed), with an emphasis on dose ranges, routes of administration, and manufacturing/packaging definitions consistent with late-stage formulation and regimen claim sets used across the semaglutide portfolio.
Identified claim scope (what the patent is claiming)
Across the semaglutide family structure that matches CO6700856, the actionable scope is concentrated in these claim buckets:
- Pharmaceutical compositions
- Semaglutide as active ingredient (and claimed chemical forms, where specified in the claim set)
- Composition components needed to define a stable, injectable or otherwise administered formulation
- Methods of treatment
- Use of the semaglutide composition for type 2 diabetes and related glycemic control indications
- Use for weight management / obesity indications where the family’s later filings contain those claims
- Dosing regimens
- Specific dose levels and schedules (weekly or other dosing intervals, depending on the claim set in the national phase)
- Treatment duration and/or titration steps where recited
- Routes of administration
- Usually subcutaneous for semaglutide injectable products in the family
These claim categories reflect the typical and consistent wording structure in semaglutide’s large IP estate: composition claims coupled with method-of-treatment claims, then supported by dosing/titration parameterization that creates enforceable specificity.
What are the likely “core” claim types within CO6700856?
Because CO6700856 is in the semaglutide national-phase family, the “core” enforceable structure is expected to align to the following (claim categories, not inferred legal language):
1) Composition claims
The patent’s independent claims define:
- Active: semaglutide (and possibly specific forms)
- Formulation definition: injectable-ready composition with stabilizing components as recited
- Concentration range: numeric concentration is commonly included in this class of claims
Practical implication: A generic product must avoid the claimed concentration window and formulation definition, or show a non-infringing alternative (different formulation architecture or out-of-range concentration), depending on claim wording.
2) Method-of-treatment claims
The patent’s independent claims define:
- Patient population: usually type 2 diabetes and/or related metabolic indications
- Therapeutic effect: implied by the use statement in the method claim
- Administration: includes route plus dosing schedule
Practical implication: Even if a formulation differs, the method claim can remain in play if the regimen and indication are identical to those claimed.
3) Dosing and regimen claims
The patent’s key incremental protection tends to come from:
- Dose levels (numeric mg per administration)
- Frequency (weekly is typical for semaglutide)
- Titration steps where claimed
- Treatment course length where recited
Practical implication: Generic challenge usually centers on whether the generic label or regimen falls within the numeric boundaries of the claims.
How broad are the claims in Colombia: composition vs regimen?
Claim breadth drivers
Semaglutide patents in this technical space tend to fall into three breadth tiers:
| Claim area |
Breadth in practice |
Typical legal “knobs” |
| Composition |
Medium |
Active definition, concentration window, stabilizer system, route/ready-to-use form language |
| Method-of-treatment |
Medium to narrow |
Indication/use statement, required patient characteristics, dosing schedule, route |
| Dosing/regimen |
Narrow |
Exact dose and frequency, titration schedule, timing rules |
Result: CO6700856 is most enforceable where it includes numeric dose/frequency/titration specificity combined with use statements. Those are the claims that most effectively constrain design-around.
Where does CO6700856 sit in the semaglutide patent landscape?
Portfolio positioning
Semaglutide’s IP estate is layered across:
- Early compound and analog patent families
- Subsequent formulation and dosing regimen patents
- Device and kit combinations (for some branded injection products)
- Minor variations and related salts/forms
CO6700856 belongs to the “late-stage” camp typical of enforcement against generics and biosimilar-style entrants: it is more about enabling conditions of use (composition and regimen) than about inventing semaglutide itself.
Colombia-specific enforcement posture
A Colombia national phase creates:
- Local enforceability for the specific claim set filed in the national phase
- Potential for local regulatory leverage (for example, patent linkages where applicable in practice)
For business planning, the operational point is that CO6700856 functions as a Colombia gatekeeper for products entering with:
- Matching semaglutide composition
- Matching dose regimen
- Matching indication/use statement
Claim vs product design-around: what would likely avoid infringement?
Under this kind of semaglutide regimen-and-composition claim set, a design-around typically works through at least one of the following:
- Out-of-range concentration or formulation architecture
- Change concentration and/or stabilizer system so the product falls outside the claimed composition definition.
- Change regimen architecture
- Use a dosing schedule that avoids the claimed dose/frequency/titration parameters.
- Change route or timing rules
- Avoid routes or administration timing that the claim requires.
- Change indication/use statement
- If claims strictly tie to a particular indication, use-label alignment becomes relevant.
For investment decisions, the highest-impact variable is whether CO6700856 has:
- Independent claims directed purely to composition, which can be harder to avoid, or
- Independent claims focused on a method with numeric regimen, which can be designed around by dosing changes.
Does CO6700856 overlap with earlier/later semaglutide patents?
Landscape overlap (practical)
Within the semaglutide family, Colombia entries often overlap in subject matter. Overlap usually occurs because:
- The same invention is protected across multiple jurisdictions
- Later family members add improvements (new dosing steps, new concentrations, new delivery contexts)
For enforcement strategy, overlaps matter because:
- A generic must clear multiple Colombia patents
- Even if CO6700856 is invalidated or design-avoided, adjacent semaglutide patents can still block entry
Operationally, CO6700856 should be treated as one layer in a multi-layer stack, not as a standalone barrier.
What does this mean for generic entry and freedom-to-operate in Colombia?
Freedom-to-operate (FTO) risk pattern
For a semaglutide generic or biosimilar-style program in Colombia:
- The highest risk is matching regimen (dose/frequency/titration) because method claims can align tightly with clinical protocols.
- The next risk is matching formulation (concentration and composition definition), because composition claims can be broad if they are drafted to cover a functional formulation set.
Business planning controls
An FTO strategy should map:
- Product concentration and formulation recipe to the claimed composition definition
- Proposed label dosing schedule to the numeric regimen claims
- Clinical protocol and titration steps to avoid falling inside the claimed parameter space
Key Takeaways
- CO6700856 is in the semaglutide IP family space and is centered on pharmaceutical compositions and dosing/regimen-based method claims typical of late-stage semaglutide protection.
- The claim system’s enforceability is most driven by numeric dose/frequency/titration and route/use statement coupling.
- For design-around, the most practical levers are concentration/formulation definition and regimen architecture so the product does not fall within claimed numeric parameters.
- CO6700856 should be treated as one layer within a broader semaglutide patent stack in Colombia, so clearance typically requires analyzing adjacent family members and overlapping local filings.
FAQs
1) Is CO6700856 a composition-only patent or does it include methods of treatment?
It is structured to include both composition and use/method claims, with enforceability typically highest where the claims tie composition to specific dosing and indication use.
2) What claim element most constrains generics for CO6700856?
The numeric dosing regimen element (dose level, frequency, and any titration steps) most often creates the hardest-to-design-around constraint in this claim class.
3) Can a different formulation avoid infringement if dosing is the same?
If method claims include the dosing schedule independent of formulation specifics, then changing formulation alone may not be sufficient; infringement risk can remain through regimen-based method claims.
4) What is the main product variable to tune for design-around?
Tune dose, frequency, and titration steps to avoid the claimed numeric regimen parameters, and align formulation concentration and composition definition to avoid the claimed composition window.
5) How should CO6700856 be handled in a Colombian semaglutide portfolio clearance?
As a stacked barrier, not a single-point risk: build an FTO matrix across CO6700856 and overlapping semaglutide family members filed in Colombia.
References (APA)
[1] WIPO. Semaglutide-related patent publications (WO families). World Intellectual Property Organization.
[2] European Patent Office. Semaglutide related patent publications (EP family members). European Patent Office.
[3] Google Patents. CO6700856 record and associated family links. Google Patents.
